Screener
Medpace Holdings, Inc. MEDP Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $707.33M+17.2% | $706.6M+26.5% | $708.45M+32.0% | $659.9M+23.7% | $603.31M+14.2% | ||
| $48.1M+3.1% | $47.92M-17.2% | $44.92M-1.1% | $48.08M-2.3% | $46.66M+12.6% | ||
| $560.51M+17.5% | $565.1M+27.0% | $555.18M+35.0% | $518.1M+23.1% | $476.98M+12.8% | ||
| $146.82M+16.2% | $141.5M+24.6% | $153.27M+22.2% | $141.81M+26.3% | $126.34M+20.1% | ||
| 20.8%-0.2pp | 20%-0.3pp | 21.6%-1.7pp | 21.5%+0.4pp | 20.9%+1.0pp | ||
| $4.99M+363% | $5.12M-20.8% | $3.72M-52.8% | $1.52M-79.8% | $1.08M-80.3% | ||
| $4.84M+369% | $6.09M+31.0% | $3.56M-58.1% | $1.03M-84.2% | -$1.8M-134% | ||
| $151.66M+21.8% | $147.59M+24.9% | $156.83M+17.1% | $142.84M+20.3% | $124.54M+12.7% | ||
| $30.3M-11.6% | $23.72M+564% | $21.7M+28.7% | $31.7M+41.8% | $34.28M+54.9% | ||
| $121.36M+34.5% | $123.87M+8.1% | $135.13M+15.5% | $111.14M+15.3% | $90.26M+2.2% | ||
| 17.2%+2.2pp | 17.5%-3.0pp | 19.1%-2.7pp | 16.8%-1.2pp | 15%-1.8pp | ||
| $4.25+37.1% | $4.28+16.6% | $4.64+26.4% | $3.86+28.2% | $3.10+12.7% | ||
| $153.53M+15.1% | $148.41M+23.2% | $160.4M+20.7% | $148.86M+24.3% | $133.35M+18.7% | ||
| 21.7%-0.4pp | 21%-0.6pp | 22.6%-2.1pp | 22.6%+0.1pp | 22.1%+0.8pp | ||
| $146.82M+16.2% | $141.5M+24.6% | $153.27M+22.2% | $141.81M+26.3% | $126.34M+20.1% |
FAQ
- What is Medpace Holdings, Inc.'s revenue?
- Medpace Holdings, Inc. (MEDP) generated $2.8B in revenue over the trailing twelve months, up 24.7% year over year.
- Is Medpace Holdings, Inc. profitable?
- Medpace Holdings, Inc. reported $491.5M in net income over the trailing twelve months, a 17.7% net margin.
- What is Medpace Holdings, Inc.'s earnings per share?
- Medpace Holdings, Inc.'s diluted EPS over the trailing twelve months is $17.03.
- Where does Medpace Holdings, Inc.'s income statement data come from?
- Every line is extracted from Medpace Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
